Zhong Jin Zai Xian·2025-12-23 08:33Core Insights - Dain Pharmaceutical has launched the melatonin granules, Manlejing®, for the treatment of sleep disorders in children with neurodevelopmental disorders, marking it as the only approved melatonin medication in China for this purpose [1][2] - The introduction of Manlejing® addresses a significant health challenge, as nearly half of children with conditions like autism spectrum disorder and attention deficit hyperactivity disorder experience sleep issues that affect their overall development [1] Group 1 - Manlejing® is designed in a granule form with a sweet taste, making it easier for children to consume [1] - Clinical studies indicate that after two weeks of using Manlejing®, children's sleep onset latency is reduced by over 36 minutes, significantly alleviating difficulties in falling asleep [2] - Continuous use of Manlejing® leads to improvements in both nighttime sleep and daytime behavior, helping to reduce issues such as hyperactivity, irritability, and inappropriate language [2] Group 2 - The International Pediatric Sleep Association (IPSA) and the American Academy of Neurology (AAN) recommend that children use pharmaceutical-grade melatonin, reinforcing the credibility of Manlejing® [2] - JD Health plans to leverage its robust pharmaceutical health service ecosystem to collaborate with Dain Pharmaceutical and other renowned companies to introduce cutting-edge therapeutic drugs, aiming to provide comprehensive digital health management solutions for affected children [2]